Related Experiment Video
Updated: Feb 22, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.6K
Tofacitinib in psoriatic arthritis.
Ting-Shun Wang1,2, Tsen-Fang Tsai2
1Division of Dermatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
Immunotherapy
|October 3, 2017
Summary
Tofacitinib, a Janus kinase inhibitor, shows significant efficacy in treating psoriatic arthritis, improving skin, enthesitis, and dactylitis symptoms compared to placebo.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Psoriatic arthritis (PsA) is a complex inflammatory condition with significant unmet treatment needs.
- Biologics have improved PsA management, but novel therapeutic targets are still required.
- Tofacitinib, a Janus kinase (JAK) inhibitor, is approved for rheumatoid arthritis and psoriasis.
Purpose of the Study:
- To review the efficacy and safety of tofacitinib for treating psoriatic arthritis.
- To evaluate tofacitinib's effectiveness in improving key PsA manifestations.
Main Methods:
- Review of evidence from Phase III clinical trials (OPAL BROADEN, OPAL BEYOND) and an open-label extension study (OPAL BALANCE).
- Assessment of American College of Rheumatology (ACR) 20% improvement criteria response rates.
- Evaluation of effects on skin lesions, enthesitis, and dactylitis.
Main Results:
- Tofacitinib (5 or 10 mg twice daily) demonstrated superiority over placebo in achieving ACR20 response at 3 months.
- Significant improvements were observed in skin manifestations, enthesitis, and dactylitis in the tofacitinib groups.
- The safety profile was evaluated through the clinical trial data.
Conclusions:
- Tofacitinib represents a promising oral treatment option for managing psoriatic arthritis.
- The drug effectively targets multiple domains of psoriatic arthritis, including skin and joint symptoms.
- Further research may solidify tofacitinib's role in the PsA treatment landscape.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
610
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
610
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
583
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
583
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
547
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
547
01:29Inflammatory Bowel Disease IV: Pharmacological Management
832
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
832
01:29Drugs for Treatment of Ulcerative Colitis in IBD
553
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
553
01:24T Cell Types and Functions
2.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K